New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:56 EDTJNJJohnson & Johnson sees FY net interest expense $400M-$500M
Says early Q1 data shows continued softer utilization trends impacted by the severe winter conditions. Says data shows continued slight declines in the rates of surgical and lab procedures in the U.S., similar to what was seen over the past 12 months. Says strong Q4 utilization in orthopedic procedures softened in Q1 due to some seasonality. Says confident overall about the long-term health of the market as economic conditions continue to recover. Says Japanese yen to be a headwind in 2014, although that negative impact to gross margin will increase throughout the year. Sees FY14 net interest expense $400M-$500M, effective tax rate 19%-20%. Says guidance for 2014 anticipates that the R&D tax credit will be renewed by Congress. Says expects continued pricing pressure in 2014 across many markets, particularly in Europe; says impact of this negative pricing pressure to negatively impact pretax operating margin by approximately 50bps. Says "comfortable" with models reflecting an operational sales increase on a constant currency basis of 5%-6% for the year. Says if currency exchange rates for all of 2014 were to remain where they were as of last week, sales growth rate would decrease by nearly half a percent. Says this would result in sales for 2014 on a constant currency basis of approximately $74.9B-$75.7B. Says that if exchange rates for all of 2014 were to remain where they were as of last week, then our reported EPS excluding special items would be positively impacted by approximately 6c per share due solely to exchange rate fluctuations. Comments made on the Q1 earnings conference call.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
08:07 EDTJNJFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
07:50 EDTJNJDoctors continue to use morcellators despite FDA warning, J&J halt, WSJ says
Subscribe for More Information
07:07 EDTJNJSynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
September 17, 2014
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
September 16, 2014
07:31 EDTJNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
September 11, 2014
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use